mezagitamab: an anti-cd38 antibody for r/r mm
Published 4 years ago • 234 plays • Length 1:14Download video MP4
Download video MP3
Similar videos
-
4:35
myeloma updates: tak-079, quadruplet regimens, mrd & bone disease
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
-
3:41
emerging therapies for r/r myeloma
-
0:47
novel agents being explored for the treatment of immune-mediated ttp
-
1:18
the mechanism of action of anti-cd47 antibodies & where these may fit in the mds treatment landscape
-
1:50
novel treatment regimens under investigation for richter's transformation
-
0:52
highlights from icle 2022
-
2:57
novel targeted therapies for the treatment of bpdcn
-
1:03
insights into the cartitude-6 trial: rationale and design
-
2:48
the promise of pyruvate kinase activators, such as mitapivat, for treating scd and thalassemia
-
3:28
molecular prognostication in smm
-
4:18
novel drugs in the r/r mm: imids
-
2:42
results from majestec-1: health-related quality of life with teclistamab in patients with r/r mm
-
1:53
the future of multiple myeloma treatment
-
1:26
avatrombopag, rilzabrutinib and covid-19 updates in itp
-
2:17
the unmet needs of patients who have visual impairment as a consequence of scd
-
2:03
unmet needs in immune thrombocytopenia